Automate Your Wheel Strategy on CLLS
With Tiblio's Option Bot, you can configure your own wheel strategy including CLLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLLS
- Rev/Share 0.4756
- Book/Share 1.1602
- PB 1.4221
- Debt/Equity 0.7897
- CurrentRatio 1.6721
- ROIC -0.2741
- MktCap 170111708.0
- FreeCF/Share 0.25
- PFCF 6.7947
- PE -2.7301
- Debt/Assets 0.2521
- DivYield 0
- ROE -0.461
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts.
Read More
Cellectis to Report First Quarter Financial Results on May 12, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.
Read More
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Published: April 22, 2025 by: MarketBeat
Sentiment: Positive
Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.
Read More
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Published: March 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Sebastiaan van der Schoot - Kempen Silvan Tuerkcan - Citizens Jack Allen - Baird Hangfei Fu - Jefferies Operator Good day, everyone, and welcome to today's Cellectis Full Year 2024 Earnings Conference Call.
Read More
Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.
Read More
About Cellectis S.A. (CLLS)
- IPO Date 2015-03-24
- Website https://www.cellectis.com
- Industry Biotechnology
- CEO Andre Choulika
- Employees 216